<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A645F804-CDF1-470E-9037-5E30E13607BB"><gtr:id>A645F804-CDF1-470E-9037-5E30E13607BB</gtr:id><gtr:name>International BFM Study Group (I-BFM SG)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Medicine and Biomedical Science</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A645F804-CDF1-470E-9037-5E30E13607BB"><gtr:id>A645F804-CDF1-470E-9037-5E30E13607BB</gtr:id><gtr:name>International BFM Study Group (I-BFM SG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3434EFD8-9DAC-49B9-9981-FD875519A53E"><gtr:id>3434EFD8-9DAC-49B9-9981-FD875519A53E</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Peto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7D8C5292-AD45-4A9B-9283-E92B9751F973"><gtr:id>7D8C5292-AD45-4A9B-9283-E92B9751F973</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Malcolm</gtr:otherNames><gtr:surname>Hann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4855B3F5-D262-4B20-9C25-645B5000285A"><gtr:id>4855B3F5-D262-4B20-9C25-645B5000285A</gtr:id><gtr:firstName>Ajay</gtr:firstName><gtr:surname>Vora</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8C4F2A80-FE74-42EF-B510-4492B6457378"><gtr:id>8C4F2A80-FE74-42EF-B510-4492B6457378</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Mitchell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300130"><gtr:id>51DB71AF-A6F8-4A57-986D-E1A0B9EEC751</gtr:id><gtr:title>UNITED KINGDOM CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA RANDOMISED TRIAL 2003 (MRC UKALL 2003)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300130</gtr:grantReference><gtr:abstractText>Acute Lymphoblastic Leukaemia is the single most common cause of cancer in children. Clinical trials conducted by a network of childhood cancer specialists supported by the Medical Research Council have contributed to the current relatively good cure rate for this leukaemia. However, initial treatment fails in around 25% of patients and they require very toxic and expensive further therapy which is not effective for many children. Also, some of those who are cured develop physical, mental and social problems in adult life due to the toxicity of their leukaemia therapy. This trial seeks to make two improvements in the treatment of children with ALL. First, to increase the success of initial treatment so that the disease recurs (comes back) in fewer patients. Second, reduce the treatment for patients who have a low risk of recurrence so that they have less immediate and late treatment-related problems. Both these aims could be fulfilled by tailoring treatment to the risk of recurrence using a new test called Minimal Residual Disease (MRD) which allows a very accurate prediction of this risk. Using genetic technology for measuring Minimal Residual Disease, we can detect and quantify 1 leukaemic cell mixed in with 10,000 normal cells. The level of leukaemia detected by this technique after 28 days of treatment accurately separates those patients with a greater than 90% chance of cure (good risk) from those with a less than 75% chance (high risk). This trial will ask the following two questions: (1) Can patients defined as good risk by the MRD test achieve the same cure rate as at present but with less treatment so that they have fewer immediate and late side-effects of therapy? (2)Can the chance of cure for patients defined as high risk by the MRD test be improved by giving them more treatment? In addition to looking at the chances of survival and leukaemia recurrence, we will also assess the impact of these treatment changes on patient and family quality of life and health service economics.</gtr:abstractText><gtr:technicalSummary>On-treatment monitoring and detection of sub-microscopic levels of leukaemia (Minimal Residual Disease or MRD assessment) is the best predictor of relapse risk in children with Acute Lymphoblastic leukaemia (ALL). The primary aim of this randomised trial will be to optimise treatment of childhood ALL and minimise its toxicity by using Minimal Residual Disease (MRD) assessment for stratification of treatment according to relapse risk. The treatment randomisations will test two hypotheses. First, that post-remission therapy can be reduced (along with its acute and long-term side-effects) for a sub-group of patients with rapid clearance of MRD during induction therapy without compromising their current excellent cure rate. Second, that patients with slow clearance of MRD will benefit from further intensification of post-remission therapy. Over its 6 year life span, the trial will accrue over 90% of newly diagnosed children with ALL in the UK and Ireland (approximately 350/annum). Minimal Residual Disease will be assessed at day 28 of treatment by a centrally co-ordinated network of 5 laboratories in the UK working to a standardised Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) method for detection of clonal antigen receptor gene rearrangements. Stratification and randomised allocation of treatment based on the day 28 MRD result will be done centrally by the Oxford Clinical Trial Service Unit. Primary end-points of the trial will be event-free and overall survival by randomised treatment. Secondary end-points will include health economic and quality of life assessments. 

Additional studies will address questions relating to asparaginase and thiopurine therapy, and biological, pharmacogenetic and pharmacokinetic determinants of treatment response.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1060536</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>International BFM Study Group (I-BFM SG)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>I-BFM</gtr:description><gtr:id>FD404D69-E955-4CEA-AF25-6364ADA58BFB</gtr:id><gtr:impact>17658395 19657114 19212338</gtr:impact><gtr:outcomeId>76DC5743203-1</gtr:outcomeId><gtr:partnerContribution>International childhood leukaemia network which has resulted in collaborative group studies for rare types of leukaemia in childhood</gtr:partnerContribution><gtr:piContribution>Contributed to the design of Infant ALL study and recruited patients to it</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of preliminary results of the trial</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>EF11EF2E-2F88-4C5F-AFF6-489ECD3852A2</gtr:id><gtr:impact>Presented to a meeting of Leukaemia Research fund-raisers and was interviewed on GMTV

Leukaemia Research has received donations directly as a result of these activities</gtr:impact><gtr:outcomeId>68CC5568DD8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Training Fellowship (2006)</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>DEB79339-BDC7-47F2-ABE0-95D7A022DD8D</gtr:id><gtr:outcomeId>9A1094635950</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Project Grant (2011)</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>F7F41D56-C08F-44EB-BE10-7CB0290FC689</gtr:id><gtr:outcomeId>8F42817F1350</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Project Grant (2010)</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>08AABA71-ACFF-421B-865E-EFB139BC01CD</gtr:id><gtr:outcomeId>qSuGuFv6abR0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in review published in British Journal of Haematology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>E3B3131C-75F4-4DDB-9A73-BB85690DE971</gtr:id><gtr:impact>Change in clinical practice</gtr:impact><gtr:outcomeId>EeBL2mH4vx6</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>84286392-8E1F-4ED0-9399-663AA68B1014</gtr:id><gtr:title>A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f73f39a7ff5ba5fd180eff29c15d2c75"><gtr:id>f73f39a7ff5ba5fd180eff29c15d2c75</gtr:id><gtr:otherNames>Pieters R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>242002EDF30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81AC22A1-915A-4A08-90DA-C8E844040683</gtr:id><gtr:title>Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c666576519c34effd47e19d2a1be0b7"><gtr:id>1c666576519c34effd47e19d2a1be0b7</gtr:id><gtr:otherNames>Madureira AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>FR7h2Y5qDX5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FED5B368-D507-468C-A09F-B77207ACAF71</gtr:id><gtr:title>Improved outcome of allogeneic haemopoietic stem cell transplantation for children with Philadelphia positive acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85a7f07ce7bc4f031236008a62850c0d"><gtr:id>85a7f07ce7bc4f031236008a62850c0d</gtr:id><gtr:otherNames>Garg A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_13971_21_22118711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0A93318-E400-4D21-B34B-E504716529DD</gtr:id><gtr:title>Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dd64a3dfe5a823e7fb4acb181251030"><gtr:id>4dd64a3dfe5a823e7fb4acb181251030</gtr:id><gtr:otherNames>Krishnan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>WPpCm1qSFnC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFB30445-9F77-45A4-832B-F7144AA65C7A</gtr:id><gtr:title>Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4306522c4553baffbe88b7dbfef99965"><gtr:id>4306522c4553baffbe88b7dbfef99965</gtr:id><gtr:otherNames>Moorman AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>DCSb5NKh3T7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5DE9C88-F344-44F2-AE35-369E116CB320</gtr:id><gtr:title>Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4306522c4553baffbe88b7dbfef99965"><gtr:id>4306522c4553baffbe88b7dbfef99965</gtr:id><gtr:otherNames>Moorman AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>545262335c0180.63379961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD5D1B47-DD26-41B0-946F-63DE4ACE7440</gtr:id><gtr:title>Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e91e51ae8da51e169650b724c095747"><gtr:id>5e91e51ae8da51e169650b724c095747</gtr:id><gtr:otherNames>Ensor HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pqztAR5iLiF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83609954-8461-4B63-A578-B95AFC4FB944</gtr:id><gtr:title>What is the minimum level of donor chimerism necessary to sustain transfusion independence in thalassaemia?</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7294ed6c2f661ff040432214b36521f2"><gtr:id>7294ed6c2f661ff040432214b36521f2</gtr:id><gtr:otherNames>Alfred A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_13971_21_20729924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B450C855-2DD1-47E9-8ADF-7779AEDE9A99</gtr:id><gtr:title>Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7b2cecd30772d1f9a48ac2fedbfed32"><gtr:id>e7b2cecd30772d1f9a48ac2fedbfed32</gtr:id><gtr:otherNames>Vora A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_13971_21_23395119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5AC7B0F-3C68-4EBE-87CD-1D4D88B49C8B</gtr:id><gtr:title>Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7559a73056a1a7d7735c78f495a3f764"><gtr:id>7559a73056a1a7d7735c78f495a3f764</gtr:id><gtr:otherNames>Lennard L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_13971_21_23252716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5121A078-4691-42C9-BA38-04D9F732F96E</gtr:id><gtr:title>'Stroke-like syndrome' caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4de781fcec363ef270f7c97aa412cc5"><gtr:id>f4de781fcec363ef270f7c97aa412cc5</gtr:id><gtr:otherNames>Bond J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13971_21_23149600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48B3F2D8-2701-4D23-8CD7-24896C043A3A</gtr:id><gtr:title>Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ab45e2374bc8925368055e8466bd49d"><gtr:id>6ab45e2374bc8925368055e8466bd49d</gtr:id><gtr:otherNames>Escherich G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>Ew2V1XGfUjn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FA34DE0-F4F4-45A8-9D50-FC740F13848A</gtr:id><gtr:title>Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd8512582a2495e8042a388a114ad30"><gtr:id>acd8512582a2495e8042a388a114ad30</gtr:id><gtr:otherNames>Jenkinson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13971_21_22814294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3A6F259-FD02-47A0-A308-3CC61F146C48</gtr:id><gtr:title>Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3197cf7b00d16897a3508773e2c77bdd"><gtr:id>3197cf7b00d16897a3508773e2c77bdd</gtr:id><gtr:otherNames>van der Linden MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>581562C09B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>059523E3-FE85-4A7E-BB3C-7EDDE54092E8</gtr:id><gtr:title>How I treat ALL in Down's syndrome: pathobiology and management.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2c38d595747b53774149ca46518daa4"><gtr:id>d2c38d595747b53774149ca46518daa4</gtr:id><gtr:otherNames>Izraeli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54526233d19ba3.23434981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67E33727-A670-4157-8E65-7214D30F1816</gtr:id><gtr:title>Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0224f405e6ee131fd07f98f5d142cf2d"><gtr:id>0224f405e6ee131fd07f98f5d142cf2d</gtr:id><gtr:otherNames>Van der Velden VH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>68A4E77CB5D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>175749D5-EA12-405E-AE34-7BBA18990E43</gtr:id><gtr:title>BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/847647222965962de271770b37cf8f6d"><gtr:id>847647222965962de271770b37cf8f6d</gtr:id><gtr:otherNames>Buitenkamp TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13971_21_22868968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9F91BE9-F851-48E4-9664-644BBE06E2E5</gtr:id><gtr:title>MRD stratification for paediatric ALL.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42823a4563d02642fed31691b876daa6"><gtr:id>42823a4563d02642fed31691b876daa6</gtr:id><gtr:otherNames>Mitchell C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>54526235044311.16254866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36E56D7E-347E-4FA3-BA3E-DF8E816F06BD</gtr:id><gtr:title>Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bb44055addc49aa0cd8597bab6d63be"><gtr:id>7bb44055addc49aa0cd8597bab6d63be</gtr:id><gtr:otherNames>Samarasinghe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_13971_21_22372373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB251A27-ED64-4A79-B9AF-86EDF59B99A1</gtr:id><gtr:title>Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74aa937fed90715883194d901be2b086"><gtr:id>74aa937fed90715883194d901be2b086</gtr:id><gtr:otherNames>Patrick K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5452623430c1a9.90780056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>351E87CA-915B-40C7-849C-9482ED8F6A7A</gtr:id><gtr:title>Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4de781fcec363ef270f7c97aa412cc5"><gtr:id>f4de781fcec363ef270f7c97aa412cc5</gtr:id><gtr:otherNames>Bond J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>UPfZcUj7pjQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B8A6E69-8AC1-40E3-B01B-E9E84FFC30B3</gtr:id><gtr:title>Postexposure chickenpox prophylaxis in children with leukaemia: a reply to the recent PEPtalk study and report of a service evaluation in a tertiary paediatric haematology centre in the UK.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f4e5abdffc07ea3b1bb521696d8947"><gtr:id>b1f4e5abdffc07ea3b1bb521696d8947</gtr:id><gtr:otherNames>Samuelson CV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>pm_13971_21_22523432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>371889C9-00D9-4465-81F4-0123BD8D8649</gtr:id><gtr:title>Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/847647222965962de271770b37cf8f6d"><gtr:id>847647222965962de271770b37cf8f6d</gtr:id><gtr:otherNames>Buitenkamp TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13971_21_22441210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C98F980C-B025-4C54-8CF6-61922A75B6EE</gtr:id><gtr:title>Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/463933391c12eae570d0e95722351f29"><gtr:id>463933391c12eae570d0e95722351f29</gtr:id><gtr:otherNames>Qureshi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>q3rZw9dkybB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAF8D832-4527-4C9C-914E-FA868156BA27</gtr:id><gtr:title>The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/935f4d30b5993d70ca04551e7b8eea7b"><gtr:id>935f4d30b5993d70ca04551e7b8eea7b</gtr:id><gtr:otherNames>Hunger SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>pm_13971_21_23024117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E7E3041-57B2-4904-A118-60358A08CE09</gtr:id><gtr:title>Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bb44055addc49aa0cd8597bab6d63be"><gtr:id>7bb44055addc49aa0cd8597bab6d63be</gtr:id><gtr:otherNames>Samarasinghe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5452623333cf74.82713091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42E6C994-831E-454A-93D0-120B6B282C5B</gtr:id><gtr:title>Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d2b3224f035002eba047d87fee5370f"><gtr:id>7d2b3224f035002eba047d87fee5370f</gtr:id><gtr:otherNames>Enshaei A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>545262330f1c45.60111442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDBE8A47-2335-4BEE-ACFF-49035B346DD6</gtr:id><gtr:title>An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d41f5af295a34b16fb752ae41433123"><gtr:id>2d41f5af295a34b16fb752ae41433123</gtr:id><gtr:otherNames>Harrison CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>545262338170e6.34444292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EABE3945-788C-4039-A22C-959663166504</gtr:id><gtr:title>Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd148054ced74283132f9a4da78302e"><gtr:id>dfd148054ced74283132f9a4da78302e</gtr:id><gtr:otherNames>O'Connor D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>ksiHxv698Rw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16A34ABE-85CA-4DBC-B178-64D237EA3B5A</gtr:id><gtr:title>Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4306522c4553baffbe88b7dbfef99965"><gtr:id>4306522c4553baffbe88b7dbfef99965</gtr:id><gtr:otherNames>Moorman AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>4D8D97EF6F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>656BAA0A-56B1-4334-B9D4-9DAD90E29DCF</gtr:id><gtr:title>A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4306522c4553baffbe88b7dbfef99965"><gtr:id>4306522c4553baffbe88b7dbfef99965</gtr:id><gtr:otherNames>Moorman AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54526234d285f1.41269451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4A7BB65-0810-4F5F-AC75-C3117AE6D83D</gtr:id><gtr:title>Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7b2cecd30772d1f9a48ac2fedbfed32"><gtr:id>e7b2cecd30772d1f9a48ac2fedbfed32</gtr:id><gtr:otherNames>Vora A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>6F0C7465861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2142ACCA-8988-4253-8822-67CFCFD11CDA</gtr:id><gtr:title>Clinical outcomes and health-related quality of life (HRQOL) following haemopoietic stem cell transplantation (HSCT) for paediatric leukaemia.</gtr:title><gtr:parentPublicationTitle>Child: care, health and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98860b862bae6b854b775e796bf60e9"><gtr:id>f98860b862bae6b854b775e796bf60e9</gtr:id><gtr:otherNames>Clarke SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1862</gtr:issn><gtr:outcomeId>djbXiP9YM3o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>907BA1F1-B71E-4CBB-B474-347EA2FDAC2F</gtr:id><gtr:title>Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21aebcaa9e2aa0bbf1ea227d0e8a7edf"><gtr:id>21aebcaa9e2aa0bbf1ea227d0e8a7edf</gtr:id><gtr:otherNames>Mann G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>EZCo9MVLmyM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48FDBE48-91BE-49A7-B865-0331C539B6FB</gtr:id><gtr:title>Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: how reliable is it and how can we optimize its use?</gtr:title><gtr:parentPublicationTitle>Journal of pediatric hematology/oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0717f101f08b1801e9f1e0f79e1c0298"><gtr:id>0717f101f08b1801e9f1e0f79e1c0298</gtr:id><gtr:otherNames>Sethuraman C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1077-4114</gtr:issn><gtr:outcomeId>AXcpadJvmJq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A40505BE-E6E0-4EF1-BFF3-425CC1C5626F</gtr:id><gtr:title>Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7b2cecd30772d1f9a48ac2fedbfed32"><gtr:id>e7b2cecd30772d1f9a48ac2fedbfed32</gtr:id><gtr:otherNames>Vora A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>54526234a18511.00618976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A48E91E-0FA7-40BE-94D7-ED5E534F6D68</gtr:id><gtr:title>The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42823a4563d02642fed31691b876daa6"><gtr:id>42823a4563d02642fed31691b876daa6</gtr:id><gtr:otherNames>Mitchell C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>8ABA7562DF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B559E87A-64DC-4458-B471-BA7800DA59D9</gtr:id><gtr:title>Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd148054ced74283132f9a4da78302e"><gtr:id>dfd148054ced74283132f9a4da78302e</gtr:id><gtr:otherNames>O'Connor D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54526234764632.50428739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61AB74F8-CDED-4CF9-A6C5-E4886C465C9D</gtr:id><gtr:title>Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be9ab15173d4cefa5e726ab78bc34cc2"><gtr:id>be9ab15173d4cefa5e726ab78bc34cc2</gtr:id><gtr:otherNames>Biondi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_13971_21_22898679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F7AFE10-87D0-4E50-AE3F-408D49F6C350</gtr:id><gtr:title>Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74aa937fed90715883194d901be2b086"><gtr:id>74aa937fed90715883194d901be2b086</gtr:id><gtr:otherNames>Patrick K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>54526234061f00.84338375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37D7F347-AD65-45E9-A3CA-70DDBCC05D63</gtr:id><gtr:title>The role of routine surveillance for silent central nervous system relapse in children with acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c320d04cca441d4b9953d409941e7bb7"><gtr:id>c320d04cca441d4b9953d409941e7bb7</gtr:id><gtr:otherNames>Jorgensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_13971_21_22924660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5FDE1AB-1894-44C1-99E9-F8F67EA5BFD4</gtr:id><gtr:title>Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e201ef6417f0b8a2cb46a47d2c9ffd3"><gtr:id>0e201ef6417f0b8a2cb46a47d2c9ffd3</gtr:id><gtr:otherNames>Astwood E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_13971_21_21250969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A400BBDE-D40B-4CC9-B9FE-C0822A0081CD</gtr:id><gtr:title>Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/847647222965962de271770b37cf8f6d"><gtr:id>847647222965962de271770b37cf8f6d</gtr:id><gtr:otherNames>Buitenkamp TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54526233ac0919.21810218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F8EE00D-C8CF-4910-888A-656AE10931DF</gtr:id><gtr:title>IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8b2715d1c16f9b9d1f3591c107b062f"><gtr:id>c8b2715d1c16f9b9d1f3591c107b062f</gtr:id><gtr:otherNames>Russell LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>545262345355b6.96402108</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300130</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>